Archives

PFS benefit seen in most subgroups, including those whose disease progressed while receiving third-generation EGFR-TKIs

Significantly longer progression-free survival, but not overall survival, seen for osimertinib in unresectable EGFR-mutation NSCLC

Neoadjuvant treatment followed by surgery results in longer event-free survival for resectable, macroscopic stage III melanoma

More patients receiving asciminib than investigator-selected tyrosine kinase inhibitor had major molecular response at 48 weeks

Crinecerfont results in greater decrease from baseline in mean daily glucocorticoid dose among patients with CAH

Fewer palliative care visits seen with stepped-care model, but noninferiority seen in the Functional Assessment of Cancer Therapy-Lung score

Authors found that BMI of ≥27 shows excellent diagnostic performance

Reduction seen in risk for clinically important kidney outcomes and death from cardiovascular causes

Those receiving pulmonologist-directed treatment have less subsequent health care utilization for respiratory illness

Similarly accurate prediction seen for respiratory outcomes, but occupational eligibility and disability compensation differed